JP2004500326A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004500326A5 JP2004500326A5 JP2000620913A JP2000620913A JP2004500326A5 JP 2004500326 A5 JP2004500326 A5 JP 2004500326A5 JP 2000620913 A JP2000620913 A JP 2000620913A JP 2000620913 A JP2000620913 A JP 2000620913A JP 2004500326 A5 JP2004500326 A5 JP 2004500326A5
- Authority
- JP
- Japan
- Prior art keywords
- tetrahydro
- oxo
- naphthyridin
- nonanoic acid
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 80
- 150000001875 compounds Chemical class 0.000 claims 52
- -1 hydroxy, hydroxy Chemical group 0.000 claims 40
- 229910052739 hydrogen Inorganic materials 0.000 claims 34
- 239000001257 hydrogen Substances 0.000 claims 34
- 125000003118 aryl group Chemical group 0.000 claims 27
- 125000001424 substituent group Chemical group 0.000 claims 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 20
- 125000003545 alkoxy group Chemical group 0.000 claims 20
- 125000004321 azepin-2-yl group Chemical group [H]N1C([H])=C([H])C([H])=C([H])C([H])=C1* 0.000 claims 20
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 14
- 150000002367 halogens Chemical class 0.000 claims 14
- 150000002431 hydrogen Chemical class 0.000 claims 14
- 125000003282 alkyl amino group Chemical group 0.000 claims 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 11
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 10
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 10
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 10
- 241000124008 Mammalia Species 0.000 claims 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims 9
- 238000004519 manufacturing process Methods 0.000 claims 9
- 125000004076 pyridyl group Chemical group 0.000 claims 9
- 125000004442 acylamino group Chemical group 0.000 claims 8
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 7
- 125000004414 alkyl thio group Chemical group 0.000 claims 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 6
- 230000003042 antagnostic effect Effects 0.000 claims 6
- 125000003652 trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 5
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 5
- 150000001721 carbon Chemical group 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 229920006395 saturated elastomer Polymers 0.000 claims 5
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 claims 4
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 4
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 4
- 208000006386 Bone Resorption Diseases 0.000 claims 4
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 4
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 4
- 230000024279 bone resorption Effects 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 102000006495 integrins Human genes 0.000 claims 4
- 108010044426 integrins Proteins 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims 4
- YRKLRKQGAWLYDP-IBGZPJMESA-N (2s)-2-(2-methoxypyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(OC)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 YRKLRKQGAWLYDP-IBGZPJMESA-N 0.000 claims 3
- KYIUESBVXDONBH-FQEVSTJZSA-N (2s)-2-(2-methylpyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 KYIUESBVXDONBH-FQEVSTJZSA-N 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 230000004614 tumor growth Effects 0.000 claims 3
- AYDDTLCITNWPKO-JOCHJYFZSA-N (2R)-2-(2,3-dihydro-1-benzofuran-6-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound OC(=O)[C@H](CCC(=O)CCCCc1ccc2CCCNc2n1)c1ccc2CCOc2c1 AYDDTLCITNWPKO-JOCHJYFZSA-N 0.000 claims 2
- HGMOQTQPWKYBJF-HXUWFJFHSA-N (2R)-2-(2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound OC(=O)[C@H](CCC(=O)CCCCc1ccc2CCCNc2n1)c1cnc2OCCOc2c1 HGMOQTQPWKYBJF-HXUWFJFHSA-N 0.000 claims 2
- DGUILINMWZCQNV-OAQYLSRUSA-N (2R)-2-(2-cyclopropylpyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound OC(=O)[C@H](CCC(=O)CCCCc1ccc2CCCNc2n1)c1cnc(nc1)C1CC1 DGUILINMWZCQNV-OAQYLSRUSA-N 0.000 claims 2
- WFGOHYOLAUUXQA-HXUWFJFHSA-N (2R)-2-(2-methylpyrimidin-5-yl)-9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid Chemical compound Cc1ncc(cn1)[C@@H](CCC(=O)CCCCc1nc2NCCCc2cc1C)C(O)=O WFGOHYOLAUUXQA-HXUWFJFHSA-N 0.000 claims 2
- GORJZZGBALVRQI-OAQYLSRUSA-N (2R)-2-(6-ethoxypyridin-3-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound CCOc1ccc(cn1)[C@@H](CCC(=O)CCCCc1ccc2CCCNc2n1)C(O)=O GORJZZGBALVRQI-OAQYLSRUSA-N 0.000 claims 2
- CAVMYLVDMTYJKW-GFOWMXPYSA-N (2R)-5-hydroxy-2-(2-methylpyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound CC1=NC=C(C=N1)[C@H](C(=O)O)CCC(CCCCC1=NC=2NCCCC2C=C1)O CAVMYLVDMTYJKW-GFOWMXPYSA-N 0.000 claims 2
- CITGFEDLBWRGEJ-OZAIVSQSSA-N (2R)-5-hydroxy-2-quinolin-3-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound N1=CC(=CC2=CC=CC=C12)[C@H](C(=O)O)CCC(CCCCC1=NC=2NCCCC2C=C1)O CITGFEDLBWRGEJ-OZAIVSQSSA-N 0.000 claims 2
- QVQCBDGBIZVTMM-OAQYLSRUSA-N (2R)-5-oxo-2-(2-propan-2-ylpyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound CC(C)c1ncc(cn1)[C@@H](CCC(=O)CCCCc1ccc2CCCNc2n1)C(O)=O QVQCBDGBIZVTMM-OAQYLSRUSA-N 0.000 claims 2
- LZQMLZXBYVIKNA-LJQANCHMSA-N (2R)-5-oxo-2-pyrimidin-5-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound OC(=O)[C@H](CCC(=O)CCCCc1ccc2CCCNc2n1)c1cncnc1 LZQMLZXBYVIKNA-LJQANCHMSA-N 0.000 claims 2
- HNGVWTANWOACNX-OAQYLSRUSA-N (2R)-7,7-dimethyl-2-(2-methylpyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound Cc1ncc(cn1)[C@@H](CCC(=O)CC(C)(C)CCc1ccc2CCCNc2n1)C(O)=O HNGVWTANWOACNX-OAQYLSRUSA-N 0.000 claims 2
- OEJMPXAXGWKGQE-QFIPXVFZSA-N (2S)-2-(1-benzofuran-6-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound OC(=O)[C@@H](CCC(=O)CCCCc1ccc2CCCNc2n1)c1ccc2ccoc2c1 OEJMPXAXGWKGQE-QFIPXVFZSA-N 0.000 claims 2
- HGMOQTQPWKYBJF-FQEVSTJZSA-N (2S)-2-(2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound OC(=O)[C@@H](CCC(=O)CCCCc1ccc2CCCNc2n1)c1cnc2OCCOc2c1 HGMOQTQPWKYBJF-FQEVSTJZSA-N 0.000 claims 2
- DGUILINMWZCQNV-NRFANRHFSA-N (2S)-2-(2-cyclopropylpyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound OC(=O)[C@@H](CCC(=O)CCCCc1ccc2CCCNc2n1)c1cnc(nc1)C1CC1 DGUILINMWZCQNV-NRFANRHFSA-N 0.000 claims 2
- CBEYPRXKRIRFIJ-FQEVSTJZSA-N (2S)-2-(2-methylpyrimidin-5-yl)-7-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound Cc1ncc(cn1)[C@H](CCCCC(=O)CCc1ccc2CCCNc2n1)C(O)=O CBEYPRXKRIRFIJ-FQEVSTJZSA-N 0.000 claims 2
- FDHJJPVHTYVRIJ-NRFANRHFSA-N (2S)-2-(5-methoxypyridin-3-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound COc1cncc(c1)[C@H](CCC(=O)CCCCc1ccc2CCCNc2n1)C(O)=O FDHJJPVHTYVRIJ-NRFANRHFSA-N 0.000 claims 2
- LUCRVWWAYGIHAB-IBGZPJMESA-N (2S)-2-(5-methylpyrazin-2-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound Cc1cnc(cn1)[C@H](CCC(=O)CCCCc1ccc2CCCNc2n1)C(O)=O LUCRVWWAYGIHAB-IBGZPJMESA-N 0.000 claims 2
- GORJZZGBALVRQI-NRFANRHFSA-N (2S)-2-(6-ethoxypyridin-3-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound CCOc1ccc(cn1)[C@H](CCC(=O)CCCCc1ccc2CCCNc2n1)C(O)=O GORJZZGBALVRQI-NRFANRHFSA-N 0.000 claims 2
- CAVMYLVDMTYJKW-ANYOKISRSA-N (2S)-5-hydroxy-2-(2-methylpyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound CC1=NC=C(C=N1)[C@@H](C(=O)O)CCC(CCCCC1=NC=2NCCCC2C=C1)O CAVMYLVDMTYJKW-ANYOKISRSA-N 0.000 claims 2
- CITGFEDLBWRGEJ-WCSIJFPASA-N (2S)-5-hydroxy-2-quinolin-3-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound N1=CC(=CC2=CC=CC=C12)[C@@H](C(=O)O)CCC(CCCCC1=NC=2NCCCC2C=C1)O CITGFEDLBWRGEJ-WCSIJFPASA-N 0.000 claims 2
- QVQCBDGBIZVTMM-NRFANRHFSA-N (2S)-5-oxo-2-(2-propan-2-ylpyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound CC(C)c1ncc(cn1)[C@H](CCC(=O)CCCCc1ccc2CCCNc2n1)C(O)=O QVQCBDGBIZVTMM-NRFANRHFSA-N 0.000 claims 2
- LZQMLZXBYVIKNA-IBGZPJMESA-N (2S)-5-oxo-2-pyrimidin-5-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound OC(=O)[C@@H](CCC(=O)CCCCc1ccc2CCCNc2n1)c1cncnc1 LZQMLZXBYVIKNA-IBGZPJMESA-N 0.000 claims 2
- HNGVWTANWOACNX-NRFANRHFSA-N (2S)-7,7-dimethyl-2-(2-methylpyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound Cc1ncc(cn1)[C@H](CCC(=O)CC(C)(C)CCc1ccc2CCCNc2n1)C(O)=O HNGVWTANWOACNX-NRFANRHFSA-N 0.000 claims 2
- OEJMPXAXGWKGQE-JOCHJYFZSA-N (2r)-2-(1-benzofuran-6-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=C2C=COC2=CC([C@@H](CCC(=O)CCCCC=2N=C3NCCCC3=CC=2)C(=O)O)=C1 OEJMPXAXGWKGQE-JOCHJYFZSA-N 0.000 claims 2
- VNNKGLKYUJUPHO-HXUWFJFHSA-N (2r)-2-(2-ethoxypyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(OCC)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 VNNKGLKYUJUPHO-HXUWFJFHSA-N 0.000 claims 2
- YRKLRKQGAWLYDP-LJQANCHMSA-N (2r)-2-(2-methoxypyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(OC)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 YRKLRKQGAWLYDP-LJQANCHMSA-N 0.000 claims 2
- MWPVEEPFXLFXMA-LJQANCHMSA-N (2r)-2-(2-methoxypyrimidin-5-yl)-9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid Chemical compound C1=NC(OC)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C)=NC2=C1CCCN2 MWPVEEPFXLFXMA-LJQANCHMSA-N 0.000 claims 2
- KYIUESBVXDONBH-HXUWFJFHSA-N (2r)-2-(2-methylpyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 KYIUESBVXDONBH-HXUWFJFHSA-N 0.000 claims 2
- CBEYPRXKRIRFIJ-HXUWFJFHSA-N (2r)-2-(2-methylpyrimidin-5-yl)-7-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C)=NC=C1[C@H](C(O)=O)CCCCC(=O)CCC1=CC=C(CCCN2)C2=N1 CBEYPRXKRIRFIJ-HXUWFJFHSA-N 0.000 claims 2
- CKSPSTLZBJXIKM-MZVUKIKXSA-N (2r)-2-(2-methylpyrimidin-5-yl)-9-(6-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid Chemical compound C1([C@H](C(O)=O)CCC(=O)CCCCC=2N=C3NCC(CC3=CC=2)C)=CN=C(C)N=C1 CKSPSTLZBJXIKM-MZVUKIKXSA-N 0.000 claims 2
- RGRLZRNIQDXERL-OAQYLSRUSA-N (2r)-2-(2-tert-butylpyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C(C)(C)C)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 RGRLZRNIQDXERL-OAQYLSRUSA-N 0.000 claims 2
- FDHJJPVHTYVRIJ-OAQYLSRUSA-N (2r)-2-(5-methoxypyridin-3-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound COC1=CN=CC([C@@H](CCC(=O)CCCCC=2N=C3NCCCC3=CC=2)C(O)=O)=C1 FDHJJPVHTYVRIJ-OAQYLSRUSA-N 0.000 claims 2
- LUCRVWWAYGIHAB-LJQANCHMSA-N (2r)-2-(5-methylpyrazin-2-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C)=CN=C1[C@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 LUCRVWWAYGIHAB-LJQANCHMSA-N 0.000 claims 2
- IGYRCQAUOKNOCX-GOSISDBHSA-N (2r)-2-(6-methoxypyridazin-3-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound N1=NC(OC)=CC=C1[C@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 IGYRCQAUOKNOCX-GOSISDBHSA-N 0.000 claims 2
- XAYSGSCETLFAQC-HXUWFJFHSA-N (2r)-2-(6-methoxypyridin-3-yl)-9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid Chemical compound C1=NC(OC)=CC=C1[C@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C)=NC2=C1CCCN2 XAYSGSCETLFAQC-HXUWFJFHSA-N 0.000 claims 2
- ACNBIPIEGANMHS-HXUWFJFHSA-N (2r)-2-[2-(dimethylamino)pyrimidin-5-yl]-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(N(C)C)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 ACNBIPIEGANMHS-HXUWFJFHSA-N 0.000 claims 2
- QHDQGGPLXWADGC-LJQANCHMSA-N (2r)-2-[2-(methylamino)pyrimidin-5-yl]-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(NC)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 QHDQGGPLXWADGC-LJQANCHMSA-N 0.000 claims 2
- UPNUQZLHTJMHSH-GOSISDBHSA-N (2r)-5-oxo-2-pyrazin-2-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1([C@@H](CCC(=O)CCCCC=2N=C3NCCCC3=CC=2)C(=O)O)=CN=CC=N1 UPNUQZLHTJMHSH-GOSISDBHSA-N 0.000 claims 2
- KCXMGCPGJGKFNN-HSZRJFAPSA-N (2r)-5-oxo-2-quinolin-3-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=CC=CC2=CC([C@@H](CCC(=O)CCCCC=3N=C4NCCCC4=CC=3)C(=O)O)=CN=C21 KCXMGCPGJGKFNN-HSZRJFAPSA-N 0.000 claims 2
- PXKRBNCCUNMPMJ-HXUWFJFHSA-N (2r)-5-oxo-2-quinoxalin-2-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=CC=CC2=NC([C@@H](CCC(=O)CCCCC=3N=C4NCCCC4=CC=3)C(=O)O)=CN=C21 PXKRBNCCUNMPMJ-HXUWFJFHSA-N 0.000 claims 2
- IRXDEOIVUJASDE-GOSISDBHSA-N (2r)-9-(3-bromo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(2-methylpyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC(C(=C1)Br)=NC2=C1CCCN2 IRXDEOIVUJASDE-GOSISDBHSA-N 0.000 claims 2
- LNBYIIKGGCJLKI-OAQYLSRUSA-N (2r)-9-(3-cyclopropyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(2-ethoxypyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(OCC)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C2CC2)=NC2=C1CCCN2 LNBYIIKGGCJLKI-OAQYLSRUSA-N 0.000 claims 2
- WBNWAXSZYLDMNX-HXUWFJFHSA-N (2r)-9-(3-cyclopropyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(2-methoxypyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(OC)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C2CC2)=NC2=C1CCCN2 WBNWAXSZYLDMNX-HXUWFJFHSA-N 0.000 claims 2
- FGXZHWSARJMWBB-OAQYLSRUSA-N (2r)-9-(3-cyclopropyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(2-methylpyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C2CC2)=NC2=C1CCCN2 FGXZHWSARJMWBB-OAQYLSRUSA-N 0.000 claims 2
- MCVGEJRYKPRVRX-OAQYLSRUSA-N (2r)-9-(3-cyclopropyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(6-methoxypyridin-3-yl)-5-oxononanoic acid Chemical compound C1=NC(OC)=CC=C1[C@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C2CC2)=NC2=C1CCCN2 MCVGEJRYKPRVRX-OAQYLSRUSA-N 0.000 claims 2
- ROBTWMCHZFQAOU-OAQYLSRUSA-N (2r)-9-(3-ethenyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(2-methylpyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C=C)=NC2=C1CCCN2 ROBTWMCHZFQAOU-OAQYLSRUSA-N 0.000 claims 2
- DMHGRCAGNKKTJL-HSZRJFAPSA-N (2r)-9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxo-2-quinolin-3-ylnonanoic acid Chemical compound C1=CC=CC2=CC([C@H](C(O)=O)CCC(=O)CCCCC3=NC=4NCCCC=4C=C3C)=CN=C21 DMHGRCAGNKKTJL-HSZRJFAPSA-N 0.000 claims 2
- AYDDTLCITNWPKO-QFIPXVFZSA-N (2s)-2-(2,3-dihydro-1-benzofuran-6-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=C2CCOC2=CC([C@H](CCC(=O)CCCCC=2N=C3NCCCC3=CC=2)C(=O)O)=C1 AYDDTLCITNWPKO-QFIPXVFZSA-N 0.000 claims 2
- VNNKGLKYUJUPHO-FQEVSTJZSA-N (2s)-2-(2-ethoxypyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(OCC)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 VNNKGLKYUJUPHO-FQEVSTJZSA-N 0.000 claims 2
- MWPVEEPFXLFXMA-IBGZPJMESA-N (2s)-2-(2-methoxypyrimidin-5-yl)-9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid Chemical compound C1=NC(OC)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C)=NC2=C1CCCN2 MWPVEEPFXLFXMA-IBGZPJMESA-N 0.000 claims 2
- WFGOHYOLAUUXQA-FQEVSTJZSA-N (2s)-2-(2-methylpyrimidin-5-yl)-9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C)=NC2=C1CCCN2 WFGOHYOLAUUXQA-FQEVSTJZSA-N 0.000 claims 2
- CKSPSTLZBJXIKM-FXMQYSIJSA-N (2s)-2-(2-methylpyrimidin-5-yl)-9-(6-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid Chemical compound C1([C@@H](C(O)=O)CCC(=O)CCCCC=2N=C3NCC(CC3=CC=2)C)=CN=C(C)N=C1 CKSPSTLZBJXIKM-FXMQYSIJSA-N 0.000 claims 2
- RGRLZRNIQDXERL-NRFANRHFSA-N (2s)-2-(2-tert-butylpyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C(C)(C)C)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 RGRLZRNIQDXERL-NRFANRHFSA-N 0.000 claims 2
- IGYRCQAUOKNOCX-SFHVURJKSA-N (2s)-2-(6-methoxypyridazin-3-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound N1=NC(OC)=CC=C1[C@@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 IGYRCQAUOKNOCX-SFHVURJKSA-N 0.000 claims 2
- XAYSGSCETLFAQC-FQEVSTJZSA-N (2s)-2-(6-methoxypyridin-3-yl)-9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid Chemical compound C1=NC(OC)=CC=C1[C@@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C)=NC2=C1CCCN2 XAYSGSCETLFAQC-FQEVSTJZSA-N 0.000 claims 2
- ACNBIPIEGANMHS-FQEVSTJZSA-N (2s)-2-[2-(dimethylamino)pyrimidin-5-yl]-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(N(C)C)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 ACNBIPIEGANMHS-FQEVSTJZSA-N 0.000 claims 2
- QHDQGGPLXWADGC-IBGZPJMESA-N (2s)-2-[2-(methylamino)pyrimidin-5-yl]-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(NC)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC1=CC=C(CCCN2)C2=N1 QHDQGGPLXWADGC-IBGZPJMESA-N 0.000 claims 2
- UPNUQZLHTJMHSH-SFHVURJKSA-N (2s)-5-oxo-2-pyrazin-2-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1([C@H](CCC(=O)CCCCC=2N=C3NCCCC3=CC=2)C(=O)O)=CN=CC=N1 UPNUQZLHTJMHSH-SFHVURJKSA-N 0.000 claims 2
- KCXMGCPGJGKFNN-QHCPKHFHSA-N (2s)-5-oxo-2-quinolin-3-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=CC=CC2=CC([C@H](CCC(=O)CCCCC=3N=C4NCCCC4=CC=3)C(=O)O)=CN=C21 KCXMGCPGJGKFNN-QHCPKHFHSA-N 0.000 claims 2
- PXKRBNCCUNMPMJ-FQEVSTJZSA-N (2s)-5-oxo-2-quinoxalin-2-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=CC=CC2=NC([C@H](CCC(=O)CCCCC=3N=C4NCCCC4=CC=3)C(=O)O)=CN=C21 PXKRBNCCUNMPMJ-FQEVSTJZSA-N 0.000 claims 2
- IRXDEOIVUJASDE-SFHVURJKSA-N (2s)-9-(3-bromo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(2-methylpyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC(C(=C1)Br)=NC2=C1CCCN2 IRXDEOIVUJASDE-SFHVURJKSA-N 0.000 claims 2
- OHUPCXOWIXFSDO-SFHVURJKSA-N (2s)-9-(3-chloro-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(2-methylpyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC(C(=C1)Cl)=NC2=C1CCCN2 OHUPCXOWIXFSDO-SFHVURJKSA-N 0.000 claims 2
- LNBYIIKGGCJLKI-NRFANRHFSA-N (2s)-9-(3-cyclopropyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(2-ethoxypyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(OCC)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C2CC2)=NC2=C1CCCN2 LNBYIIKGGCJLKI-NRFANRHFSA-N 0.000 claims 2
- WBNWAXSZYLDMNX-FQEVSTJZSA-N (2s)-9-(3-cyclopropyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(2-methoxypyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(OC)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C2CC2)=NC2=C1CCCN2 WBNWAXSZYLDMNX-FQEVSTJZSA-N 0.000 claims 2
- FGXZHWSARJMWBB-NRFANRHFSA-N (2s)-9-(3-cyclopropyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(2-methylpyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C2CC2)=NC2=C1CCCN2 FGXZHWSARJMWBB-NRFANRHFSA-N 0.000 claims 2
- MCVGEJRYKPRVRX-NRFANRHFSA-N (2s)-9-(3-cyclopropyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(6-methoxypyridin-3-yl)-5-oxononanoic acid Chemical compound C1=NC(OC)=CC=C1[C@@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C2CC2)=NC2=C1CCCN2 MCVGEJRYKPRVRX-NRFANRHFSA-N 0.000 claims 2
- DMHGRCAGNKKTJL-QHCPKHFHSA-N (2s)-9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxo-2-quinolin-3-ylnonanoic acid Chemical compound C1=CC=CC2=CC([C@@H](C(O)=O)CCC(=O)CCCCC3=NC=4NCCCC=4C=C3C)=CN=C21 DMHGRCAGNKKTJL-QHCPKHFHSA-N 0.000 claims 2
- OVPGZOBAJSOERO-CQSZACIVSA-N (3r)-9-[6-(methylamino)pyridin-2-yl]-5-oxo-3-pyrimidin-5-ylnonanoic acid Chemical compound CNC1=CC=CC(CCCCC(=O)C[C@H](CC(O)=O)C=2C=NC=NC=2)=N1 OVPGZOBAJSOERO-CQSZACIVSA-N 0.000 claims 2
- OVPGZOBAJSOERO-AWEZNQCLSA-N (3s)-9-[6-(methylamino)pyridin-2-yl]-5-oxo-3-pyrimidin-5-ylnonanoic acid Chemical compound CNC1=CC=CC(CCCCC(=O)C[C@@H](CC(O)=O)C=2C=NC=NC=2)=N1 OVPGZOBAJSOERO-AWEZNQCLSA-N 0.000 claims 2
- 229940121819 ATPase inhibitor Drugs 0.000 claims 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 2
- 102000004171 Cathepsin K Human genes 0.000 claims 2
- 108090000625 Cathepsin K Proteins 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 2
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 claims 2
- 239000002834 estrogen receptor modulator Substances 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N noncarboxylic acid Natural products CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 claims 2
- 210000002997 osteoclast Anatomy 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- OHUPCXOWIXFSDO-GOSISDBHSA-N (2r)-9-(3-chloro-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(2-methylpyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1[C@H](C(O)=O)CCC(=O)CCCCC(C(=C1)Cl)=NC2=C1CCCN2 OHUPCXOWIXFSDO-GOSISDBHSA-N 0.000 claims 1
- ROBTWMCHZFQAOU-NRFANRHFSA-N (2s)-9-(3-ethenyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(2-methylpyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1[C@@H](C(O)=O)CCC(=O)CCCCC(C(=C1)C=C)=NC2=C1CCCN2 ROBTWMCHZFQAOU-NRFANRHFSA-N 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006621 (C3-C8) cycloalkyl-(C1-C6) alkyl group Chemical group 0.000 claims 1
- XKEVCUANHFBLPG-UHFFFAOYSA-N 1-(3-cyclopropyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-7-(2-methylpyrimidin-5-yl)nonan-5-one Chemical compound C=1N=C(C)N=CC=1C(CC)CC(=O)CCCCC1=NC=2NCCCC=2C=C1C1CC1 XKEVCUANHFBLPG-UHFFFAOYSA-N 0.000 claims 1
- RFARBJJIUKDADJ-UHFFFAOYSA-N 2-(3-chloro-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound CCCCCCCC(C1=C(C=C2CCCNC2=N1)Cl)C(=O)O RFARBJJIUKDADJ-UHFFFAOYSA-N 0.000 claims 1
- JBLQKEHWQSGLSN-UHFFFAOYSA-N 2-(3-cyclopropyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1(CC1)C=1C(=NC=2NCCCC=2C=1)C(C(=O)O)CCCCCCC JBLQKEHWQSGLSN-UHFFFAOYSA-N 0.000 claims 1
- ZDAZYNCFIRTHMI-UHFFFAOYSA-N 2-(3-ethenyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C(=C)C=1C(=NC=2NCCCC=2C=1)C(C(=O)O)CCCCCCC ZDAZYNCFIRTHMI-UHFFFAOYSA-N 0.000 claims 1
- QAHKIQBWURDABN-UHFFFAOYSA-N 3-(1-benzofuran-6-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=C2C=COC2=CC(C(CC(=O)CCCCC=2N=C3NCCCC3=CC=2)CC(=O)O)=C1 QAHKIQBWURDABN-UHFFFAOYSA-N 0.000 claims 1
- LHXUSLZFFIODBJ-UHFFFAOYSA-N 3-(2,3-dihydro-1-benzofuran-6-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=C2CCOC2=CC(C(CC(=O)CCCCC=2N=C3NCCCC3=CC=2)CC(=O)O)=C1 LHXUSLZFFIODBJ-UHFFFAOYSA-N 0.000 claims 1
- GBWHLRNQBCQMDU-UHFFFAOYSA-N 3-(2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound O1CCOC2=CC(C(CC(=O)CCCCC=3N=C4NCCCC4=CC=3)CC(=O)O)=CN=C21 GBWHLRNQBCQMDU-UHFFFAOYSA-N 0.000 claims 1
- SCYLAETWALMUDS-UHFFFAOYSA-N 3-(2-cyclopropylpyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C=1C=C2CCCNC2=NC=1CCCCC(=O)CC(CC(=O)O)C(C=N1)=CN=C1C1CC1 SCYLAETWALMUDS-UHFFFAOYSA-N 0.000 claims 1
- ISWGDMYFBALUTB-UHFFFAOYSA-N 3-(2-ethoxypyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(OCC)=NC=C1C(CC(O)=O)CC(=O)CCCCC1=CC=C(CCCN2)C2=N1 ISWGDMYFBALUTB-UHFFFAOYSA-N 0.000 claims 1
- CKQPZIKYRFZYFW-UHFFFAOYSA-N 3-(2-methoxypyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(OC)=NC=C1C(CC(O)=O)CC(=O)CCCCC1=CC=C(CCCN2)C2=N1 CKQPZIKYRFZYFW-UHFFFAOYSA-N 0.000 claims 1
- CQKYNXYYADIHTP-UHFFFAOYSA-N 3-(2-methoxypyrimidin-5-yl)-9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid Chemical compound C1=NC(OC)=NC=C1C(CC(O)=O)CC(=O)CCCCC(C(=C1)C)=NC2=C1CCCN2 CQKYNXYYADIHTP-UHFFFAOYSA-N 0.000 claims 1
- MMIMNHFTOYWLHW-UHFFFAOYSA-N 3-(2-methylpyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C)=NC=C1C(CC(O)=O)CC(=O)CCCCC1=CC=C(CCCN2)C2=N1 MMIMNHFTOYWLHW-UHFFFAOYSA-N 0.000 claims 1
- AXWCRKTXRMIKPF-UHFFFAOYSA-N 3-(2-methylpyrimidin-5-yl)-7-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C)=NC=C1C(CC(O)=O)CCCC(=O)CCC1=CC=C(CCCN2)C2=N1 AXWCRKTXRMIKPF-UHFFFAOYSA-N 0.000 claims 1
- HDRFULTXFCRTQX-UHFFFAOYSA-N 3-(2-methylpyrimidin-5-yl)-9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1C(CC(O)=O)CC(=O)CCCCC(C(=C1)C)=NC2=C1CCCN2 HDRFULTXFCRTQX-UHFFFAOYSA-N 0.000 claims 1
- RWGYKDBFESDGHI-UHFFFAOYSA-N 3-(2-methylpyrimidin-5-yl)-9-(6-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid Chemical compound C=1C=C2CC(C)CNC2=NC=1CCCCC(=O)CC(CC(O)=O)C1=CN=C(C)N=C1 RWGYKDBFESDGHI-UHFFFAOYSA-N 0.000 claims 1
- GWHHCGJNCXNOFE-UHFFFAOYSA-N 3-(2-tert-butylpyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C(C)(C)C)=NC=C1C(CC(O)=O)CC(=O)CCCCC1=CC=C(CCCN2)C2=N1 GWHHCGJNCXNOFE-UHFFFAOYSA-N 0.000 claims 1
- ZNBIHZSQJAURRN-UHFFFAOYSA-N 3-(5-methoxypyridin-3-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound COC1=CN=CC(C(CC(O)=O)CC(=O)CCCCC=2N=C3NCCCC3=CC=2)=C1 ZNBIHZSQJAURRN-UHFFFAOYSA-N 0.000 claims 1
- DEUWUJFNKOTTIC-UHFFFAOYSA-N 3-(5-methylpyrazin-2-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C)=CN=C1C(CC(O)=O)CC(=O)CCCCC1=CC=C(CCCN2)C2=N1 DEUWUJFNKOTTIC-UHFFFAOYSA-N 0.000 claims 1
- DAUPDEKPSWOESJ-UHFFFAOYSA-N 3-(6-ethoxypyridin-3-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(OCC)=CC=C1C(CC(O)=O)CC(=O)CCCCC1=CC=C(CCCN2)C2=N1 DAUPDEKPSWOESJ-UHFFFAOYSA-N 0.000 claims 1
- FIJQSMQSNSSYTC-UHFFFAOYSA-N 3-(6-methoxypyridazin-3-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound N1=NC(OC)=CC=C1C(CC(O)=O)CC(=O)CCCCC1=CC=C(CCCN2)C2=N1 FIJQSMQSNSSYTC-UHFFFAOYSA-N 0.000 claims 1
- LFOAWSUGJKSHHB-UHFFFAOYSA-N 3-(6-methoxypyridin-3-yl)-9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid Chemical compound C1=NC(OC)=CC=C1C(CC(O)=O)CC(=O)CCCCC(C(=C1)C)=NC2=C1CCCN2 LFOAWSUGJKSHHB-UHFFFAOYSA-N 0.000 claims 1
- JQZZSYZKNLEXOV-UHFFFAOYSA-N 3-[2-(dimethylamino)pyrimidin-5-yl]-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(N(C)C)=NC=C1C(CC(O)=O)CC(=O)CCCCC1=CC=C(CCCN2)C2=N1 JQZZSYZKNLEXOV-UHFFFAOYSA-N 0.000 claims 1
- RCTLBKVHKHPTJY-UHFFFAOYSA-N 3-[2-(methylamino)pyrimidin-5-yl]-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(NC)=NC=C1C(CC(O)=O)CC(=O)CCCCC1=CC=C(CCCN2)C2=N1 RCTLBKVHKHPTJY-UHFFFAOYSA-N 0.000 claims 1
- ZGXKNWNJVOZHCG-UHFFFAOYSA-N 5-hydroxy-3-(2-methylpyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C)=NC=C1C(CC(O)=O)CC(O)CCCCC1=CC=C(CCCN2)C2=N1 ZGXKNWNJVOZHCG-UHFFFAOYSA-N 0.000 claims 1
- ZYXRXQZAQSMRHD-UHFFFAOYSA-N 5-hydroxy-3-quinolin-3-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=CC=CC2=CC(C(CC(O)=O)CC(CCCCC=3N=C4NCCCC4=CC=3)O)=CN=C21 ZYXRXQZAQSMRHD-UHFFFAOYSA-N 0.000 claims 1
- SEELZNMZMVOEBU-UHFFFAOYSA-N 5-oxo-3-(2-propan-2-ylpyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C(C)C)=NC=C1C(CC(O)=O)CC(=O)CCCCC1=CC=C(CCCN2)C2=N1 SEELZNMZMVOEBU-UHFFFAOYSA-N 0.000 claims 1
- CBMAMSBWMAVLPB-UHFFFAOYSA-N 5-oxo-3-pyrazin-2-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C=1C=C2CCCNC2=NC=1CCCCC(=O)CC(CC(=O)O)C1=CN=CC=N1 CBMAMSBWMAVLPB-UHFFFAOYSA-N 0.000 claims 1
- GKNVSRZWLDHKCU-UHFFFAOYSA-N 5-oxo-3-pyrimidin-5-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C=1C=C2CCCNC2=NC=1CCCCC(=O)CC(CC(=O)O)C1=CN=CN=C1 GKNVSRZWLDHKCU-UHFFFAOYSA-N 0.000 claims 1
- QTYNHONNXNWXBB-UHFFFAOYSA-N 5-oxo-3-quinolin-3-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=CC=CC2=CC(C(CC(=O)CCCCC=3N=C4NCCCC4=CC=3)CC(=O)O)=CN=C21 QTYNHONNXNWXBB-UHFFFAOYSA-N 0.000 claims 1
- OGEHVFFGMRSQAU-UHFFFAOYSA-N 5-oxo-3-quinoxalin-2-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=CC=CC2=NC(C(CC(=O)CCCCC=3N=C4NCCCC4=CC=3)CC(=O)O)=CN=C21 OGEHVFFGMRSQAU-UHFFFAOYSA-N 0.000 claims 1
- KLHVJOCHLMWJPW-UHFFFAOYSA-N 9-(2,6-diaminopyrimidin-4-yl)-3-(2-methylpyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1C(CC(O)=O)CC(=O)CCCCC1=CC(N)=NC(N)=N1 KLHVJOCHLMWJPW-UHFFFAOYSA-N 0.000 claims 1
- OXBOFCJANGRIBP-UHFFFAOYSA-N 9-(3-bromo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-3-(2-methylpyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1C(CC(O)=O)CC(=O)CCCCC(C(=C1)Br)=NC2=C1CCCN2 OXBOFCJANGRIBP-UHFFFAOYSA-N 0.000 claims 1
- UWTNKCIZAXFDTL-UHFFFAOYSA-N 9-(3-chloro-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-3-(2-methylpyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1C(CC(O)=O)CC(=O)CCCCC(C(=C1)Cl)=NC2=C1CCCN2 UWTNKCIZAXFDTL-UHFFFAOYSA-N 0.000 claims 1
- CLXOWWAVRFIKSW-UHFFFAOYSA-N 9-(3-cyclopropyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-3-(2-ethoxypyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(OCC)=NC=C1C(CC(O)=O)CC(=O)CCCCC(C(=C1)C2CC2)=NC2=C1CCCN2 CLXOWWAVRFIKSW-UHFFFAOYSA-N 0.000 claims 1
- QBLMYYIXXTVYAY-UHFFFAOYSA-N 9-(3-cyclopropyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-3-(6-methoxypyridin-3-yl)-5-oxononanoic acid Chemical compound C1=NC(OC)=CC=C1C(CC(O)=O)CC(=O)CCCCC(C(=C1)C2CC2)=NC2=C1CCCN2 QBLMYYIXXTVYAY-UHFFFAOYSA-N 0.000 claims 1
- SMDKAGFIIKXBTI-UHFFFAOYSA-N 9-(3-ethenyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-3-(2-methylpyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(C)=NC=C1C(CC(O)=O)CC(=O)CCCCC(C(=C1)C=C)=NC2=C1CCCN2 SMDKAGFIIKXBTI-UHFFFAOYSA-N 0.000 claims 1
- IIDYUNBWJDCHRZ-UHFFFAOYSA-N 9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxo-3-quinolin-3-ylnonanoic acid Chemical compound C1=CC=CC2=CC(C(CC(O)=O)CC(=O)CCCCC3=NC=4NCCCC=4C=C3C)=CN=C21 IIDYUNBWJDCHRZ-UHFFFAOYSA-N 0.000 claims 1
- LLSWOFDIDNHBKI-UHFFFAOYSA-N 9-(6-amino-3,5-dimethylpyridin-2-yl)-3-(2-methoxypyrimidin-5-yl)-5-oxononanoic acid Chemical compound C1=NC(OC)=NC=C1C(CC(O)=O)CC(=O)CCCCC1=NC(N)=C(C)C=C1C LLSWOFDIDNHBKI-UHFFFAOYSA-N 0.000 claims 1
- OVPGZOBAJSOERO-UHFFFAOYSA-N 9-[6-(methylamino)pyridin-2-yl]-5-oxo-3-pyrimidin-5-ylnonanoic acid Chemical compound CNC1=CC=CC(CCCCC(=O)CC(CC(O)=O)C=2C=NC=NC=2)=N1 OVPGZOBAJSOERO-UHFFFAOYSA-N 0.000 claims 1
- 102100033367 Appetite-regulating hormone Human genes 0.000 claims 1
- 101710111255 Appetite-regulating hormone Proteins 0.000 claims 1
- AZNYSXFOKOWWGP-UHFFFAOYSA-N CC1=NC=C(C=N1)C(CC)CC(CC(CCC1=NC=2NCCCC2C=C1)(C)C)=O Chemical compound CC1=NC=C(C=N1)C(CC)CC(CC(CCC1=NC=2NCCCC2C=C1)(C)C)=O AZNYSXFOKOWWGP-UHFFFAOYSA-N 0.000 claims 1
- KZORGNLTMVMRPR-UHFFFAOYSA-N COC1=NC=C(C=N1)C(CC)CC(CCCCC1=NC=2NCCCC2C=C1C1CC1)=O Chemical compound COC1=NC=C(C=N1)C(CC)CC(CCCCC1=NC=2NCCCC2C=C1C1CC1)=O KZORGNLTMVMRPR-UHFFFAOYSA-N 0.000 claims 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 101100481404 Danio rerio tie1 gene Proteins 0.000 claims 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 229940122091 Geranylgeranyltransferase inhibitor Drugs 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 101710170181 Metalloproteinase inhibitor Proteins 0.000 claims 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims 1
- 101100481406 Mus musculus Tie1 gene Proteins 0.000 claims 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 claims 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 claims 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims 1
- 101100445392 Xenopus laevis ephb3 gene Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- DCSBSVSZJRSITC-UHFFFAOYSA-M alendronate sodium trihydrate Chemical compound O.O.O.[Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O DCSBSVSZJRSITC-UHFFFAOYSA-M 0.000 claims 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000008485 antagonism Effects 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940125436 dual inhibitor Drugs 0.000 claims 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000003324 growth hormone secretagogue Substances 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 229940126170 metalloproteinase inhibitor Drugs 0.000 claims 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 claims 1
- 230000013823 prenylation Effects 0.000 claims 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 229960005356 urokinase Drugs 0.000 claims 1
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13710199P | 1999-06-02 | 1999-06-02 | |
| US17921600P | 2000-01-31 | 2000-01-31 | |
| PCT/US2000/014901 WO2000072801A2 (en) | 1999-06-02 | 2000-05-30 | Alpha v integrin receptor antagonists |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006091925A Division JP2006206604A (ja) | 1999-06-02 | 2006-03-29 | αｖインテグリン受容体拮抗薬 |
| JP2006091926A Division JP2006232844A (ja) | 1999-06-02 | 2006-03-29 | αｖインテグリン受容体拮抗薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004500326A JP2004500326A (ja) | 2004-01-08 |
| JP2004500326A5 true JP2004500326A5 (enExample) | 2004-12-24 |
| JP3808707B2 JP3808707B2 (ja) | 2006-08-16 |
Family
ID=26834930
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000620913A Expired - Fee Related JP3808707B2 (ja) | 1999-06-02 | 2000-05-30 | αｖインテグリン受容体拮抗薬 |
| JP2006091926A Withdrawn JP2006232844A (ja) | 1999-06-02 | 2006-03-29 | αｖインテグリン受容体拮抗薬 |
| JP2006091925A Withdrawn JP2006206604A (ja) | 1999-06-02 | 2006-03-29 | αｖインテグリン受容体拮抗薬 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006091926A Withdrawn JP2006232844A (ja) | 1999-06-02 | 2006-03-29 | αｖインテグリン受容体拮抗薬 |
| JP2006091925A Withdrawn JP2006206604A (ja) | 1999-06-02 | 2006-03-29 | αｖインテグリン受容体拮抗薬 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6410526B1 (enExample) |
| EP (1) | EP1187592B1 (enExample) |
| JP (3) | JP3808707B2 (enExample) |
| KR (1) | KR20020021380A (enExample) |
| CN (1) | CN1589145A (enExample) |
| AT (1) | ATE368462T1 (enExample) |
| AU (1) | AU749351B2 (enExample) |
| BG (1) | BG106232A (enExample) |
| BR (1) | BR0011108A (enExample) |
| CA (1) | CA2373937A1 (enExample) |
| CY (1) | CY1107746T1 (enExample) |
| CZ (1) | CZ20014308A3 (enExample) |
| DE (1) | DE60035779T2 (enExample) |
| DK (1) | DK1187592T3 (enExample) |
| DZ (1) | DZ3263A1 (enExample) |
| EA (1) | EA200101272A1 (enExample) |
| EE (1) | EE200100642A (enExample) |
| ES (1) | ES2288861T3 (enExample) |
| HR (1) | HRP20010895A2 (enExample) |
| HU (1) | HUP0302468A2 (enExample) |
| IL (1) | IL146378A0 (enExample) |
| IS (1) | IS6157A (enExample) |
| NO (1) | NO323906B1 (enExample) |
| PL (1) | PL353364A1 (enExample) |
| PT (1) | PT1187592E (enExample) |
| SK (1) | SK17442001A3 (enExample) |
| TR (1) | TR200103431T2 (enExample) |
| WO (1) | WO2000072801A2 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| JP2003520271A (ja) | 2000-01-24 | 2003-07-02 | メルク エンド カムパニー インコーポレーテッド | αｖインテグリン受容体拮抗薬 |
| JP2004511434A (ja) | 2000-06-15 | 2004-04-15 | ファルマシア・コーポレーション | インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸 |
| AU7793501A (en) * | 2000-07-26 | 2002-02-05 | Merck & Co Inc | Alpha v integrin receptor antagonists |
| AU2001290772A1 (en) * | 2000-09-14 | 2002-03-26 | Merck And Co., Inc. | Alpha v integrin receptor antagonists |
| AU2001296439A1 (en) * | 2000-10-04 | 2002-04-15 | Merck & Co., Inc. | Phosphoric acid salt of an integrin receptor antagonist |
| AU2002246757B2 (en) * | 2001-01-03 | 2006-02-02 | Merck & Co., Inc. | Methods and compositions for treating periodontal disease |
| CN1247258C (zh) | 2001-04-24 | 2006-03-29 | 默克专利有限公司 | 使用抗血管生成剂和TNFα的联合疗法 |
| CA2478317A1 (en) * | 2002-03-04 | 2003-09-18 | Medimmune, Inc. | Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate |
| JP2005533001A (ja) * | 2002-03-04 | 2005-11-04 | メディミューン，インコーポレーテッド | インテグリンαｖβ３アンタゴニストを他の物質と併用投与する癌の予防または治療方法 |
| US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| BR0316876A (pt) | 2002-12-20 | 2005-10-25 | Pharmacia Corp | Compostos de tiazol e composição farmacêutica compreendendo o mesmo |
| US7288655B2 (en) * | 2003-03-07 | 2007-10-30 | Merck & Co., Inc. | α v integrin receptor antagonists |
| US8604185B2 (en) | 2004-07-20 | 2013-12-10 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
| KR20080089489A (ko) | 2006-01-18 | 2008-10-06 | 메르크 파텐트 게엠베하 | 인테그린 리간드를 사용하는 암치료용 특이적 요법 |
| EA017864B1 (ru) | 2007-01-18 | 2013-03-29 | Мерк Патент Гмбх | Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака |
| CL2008000467A1 (es) * | 2007-02-14 | 2008-08-22 | Janssen Pharmaceutica Nv | Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma |
| EP2730282A1 (en) | 2007-11-08 | 2014-05-14 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
| AU2010252280A1 (en) | 2009-05-25 | 2012-01-19 | Merck Patent Gmbh | Continuous administration of cilengitide in cancer treatments |
| EP3266782B1 (en) * | 2013-02-07 | 2019-10-30 | SciFluor Life Sciences, Inc. | Fluorinated integrin antagonists |
| US8901144B2 (en) | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| DK3929196T3 (da) | 2013-09-24 | 2023-09-25 | Fujifilm Corp | Farmaceutisk sammensætning af en nitrogenholdig forbindelse eller salt deraf, eller metalkompleks deraf |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| EP3925959A1 (en) * | 2015-02-19 | 2021-12-22 | OcuTerra Therapeutics, Inc. | Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| US10118929B2 (en) | 2016-04-27 | 2018-11-06 | Scifluor Life Sciences, Inc. | Nonanoic and decanoic acid derivatives and uses thereof |
| KR20190026001A (ko) * | 2016-07-05 | 2019-03-12 | 더 락커펠러 유니버시티 | 테트라하이드로나프티리딘펜탄아미드 인테그린 길항물질 |
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| CN110167934B (zh) * | 2016-11-08 | 2022-06-10 | 百时美施贵宝公司 | 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物 |
| AU2017359028A1 (en) * | 2016-11-08 | 2019-06-20 | Bristol-Myers Squibb Company | Azole amides and amines as alpha V integrin inhibitors |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| EP4159727B1 (en) | 2017-02-28 | 2026-04-08 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| PT3844162T (pt) | 2018-08-29 | 2025-03-28 | Morphic Therapeutic Inc | Inibidores da integrina alfa v beta6 |
| AU2019327475B2 (en) | 2018-08-29 | 2025-06-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| TW202615058A (zh) | 2024-06-12 | 2026-04-16 | 美商艾拉倫製藥股份有限公司 | 失養強直性肌肉蛋白質激酶（ｄｍｐｋ）ｉｒｎａ組成物及其使用方法 |
| WO2025259743A1 (en) | 2024-06-12 | 2025-12-18 | Alnylam Pharmaceuticals, Inc. | Dual conjugate compounds for extrahepatic delivery |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3843798A (en) | 1973-03-12 | 1974-10-22 | Stanley Drug Products Inc | Methods and compositions for inducing resistance to bacterial infections |
| US5025025A (en) | 1989-06-28 | 1991-06-18 | Ciba-Geigy Corporation | (Arylsulfonamido- and pyridyl-)-substituted carboxylic acids and derivatives thereof and use for suppressing thromboxane activity |
| FI934894L (fi) | 1991-05-07 | 1993-11-05 | Merck & Co Inc | Fibrinogenreceptorantagonister |
| JPH07503944A (ja) | 1991-11-22 | 1995-04-27 | イエダ リサーチ アンド デベロツプメント カンパニー リミテツド | Ａｒｇ−ｇｌｙ−ａｓｐ配列の非ペプチド代替物およびそれらからなる医薬組成物 |
| EP0667773A4 (en) | 1992-10-14 | 1996-09-25 | Merck & Co Inc | FIBRINOGEN RECEPTOR ANTAGONISTS. |
| ATE227567T1 (de) | 1994-05-27 | 2002-11-15 | Merck & Co Inc | Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption |
| EP0880511A4 (en) | 1996-01-16 | 1999-06-16 | Merck & Co Inc | Integrin receptor antagonists |
| ATE212990T1 (de) | 1996-03-20 | 2002-02-15 | Hoechst Ag | Inhibitoren der knochenresorption und vitronectinrezeptor-antagonisten |
| ES2185009T3 (es) | 1996-04-10 | 2003-04-16 | Merck & Co Inc | Antagonistas de alfa y beta 3'. |
| US5668159A (en) | 1996-05-08 | 1997-09-16 | The Dupont Merck Pharmaceutical Company | 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists |
| JP2002511052A (ja) | 1996-08-29 | 2002-04-09 | メルク エンド カンパニー インコーポレーテッド | インテグリンアンタゴニスト |
| CA2268940A1 (en) * | 1996-10-30 | 1998-05-07 | Merck & Co., Inc. | Integrin antagonists |
| JP2001504456A (ja) | 1996-10-30 | 2001-04-03 | メルク エンド カンパニー インコーポレーテッド | インテグリン拮抗薬 |
| CA2277273C (en) | 1997-01-17 | 2008-03-25 | Merck & Co., Inc. | Integrin antagonists |
| US6017926A (en) | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
| SK9192000A3 (en) * | 1997-12-17 | 2001-03-12 | Merck & Co Inc | Integrin receptor antagonists |
| ES2243016T3 (es) | 1997-12-17 | 2005-11-16 | MERCK & CO., INC. | Antagonistas de receptores de integrinas. |
| EP1047425A4 (en) | 1997-12-17 | 2009-04-22 | Merck & Co Inc | INTEGRIN RECEPTOR ANTAGONISTS |
| DE69830806T2 (de) | 1997-12-17 | 2006-04-27 | Merck & Co., Inc. | Integrinrezeptor antagonisten |
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
-
2000
- 2000-05-30 DE DE60035779T patent/DE60035779T2/de not_active Expired - Fee Related
- 2000-05-30 ES ES00942652T patent/ES2288861T3/es not_active Expired - Lifetime
- 2000-05-30 TR TR2001/03431T patent/TR200103431T2/xx unknown
- 2000-05-30 CA CA002373937A patent/CA2373937A1/en not_active Abandoned
- 2000-05-30 AT AT00942652T patent/ATE368462T1/de not_active IP Right Cessation
- 2000-05-30 KR KR1020017015498A patent/KR20020021380A/ko not_active Ceased
- 2000-05-30 CZ CZ20014308A patent/CZ20014308A3/cs unknown
- 2000-05-30 IL IL14637800A patent/IL146378A0/xx unknown
- 2000-05-30 HR HR20010895A patent/HRP20010895A2/xx not_active Application Discontinuation
- 2000-05-30 PT PT00942652T patent/PT1187592E/pt unknown
- 2000-05-30 PL PL00353364A patent/PL353364A1/xx not_active Application Discontinuation
- 2000-05-30 DK DK00942652T patent/DK1187592T3/da active
- 2000-05-30 AU AU57246/00A patent/AU749351B2/en not_active Ceased
- 2000-05-30 EE EEP200100642A patent/EE200100642A/xx unknown
- 2000-05-30 DZ DZ003263A patent/DZ3263A1/fr active
- 2000-05-30 CN CNA00811157XA patent/CN1589145A/zh active Pending
- 2000-05-30 WO PCT/US2000/014901 patent/WO2000072801A2/en not_active Ceased
- 2000-05-30 HU HU0302468A patent/HUP0302468A2/hu unknown
- 2000-05-30 BR BR0011108-2A patent/BR0011108A/pt not_active IP Right Cessation
- 2000-05-30 EP EP00942652A patent/EP1187592B1/en not_active Expired - Lifetime
- 2000-05-30 SK SK1744-2001A patent/SK17442001A3/sk unknown
- 2000-05-30 JP JP2000620913A patent/JP3808707B2/ja not_active Expired - Fee Related
- 2000-05-30 EA EA200101272A patent/EA200101272A1/ru unknown
- 2000-05-31 US US09/583,522 patent/US6410526B1/en not_active Expired - Fee Related
-
2001
- 2001-11-13 IS IS6157A patent/IS6157A/is unknown
- 2001-11-30 NO NO20015858A patent/NO323906B1/no not_active IP Right Cessation
- 2001-12-18 BG BG106232A patent/BG106232A/xx unknown
-
2006
- 2006-03-29 JP JP2006091926A patent/JP2006232844A/ja not_active Withdrawn
- 2006-03-29 JP JP2006091925A patent/JP2006206604A/ja not_active Withdrawn
-
2007
- 2007-09-27 CY CY20071101242T patent/CY1107746T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003520271A5 (enExample) | ||
| JP7654071B2 (ja) | 複素環スピロ化合物及び使用方法 | |
| CA2397194A1 (en) | Alpha v integrin receptor antagonists | |
| ES2974985T3 (es) | Inhibidores de FGFR y métodos de uso de los mismos | |
| JP7380507B2 (ja) | Ｓｔｉｎｇ作動化合物 | |
| TW201822764A (zh) | Syk抑制劑 | |
| JP2023550466A5 (enExample) | ||
| EP4334298A1 (en) | Urea derivatives which can be used to treat cancer | |
| KR102891807B1 (ko) | 치료 헤테로시클릭 화합물 | |
| RU2019120986A (ru) | Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2 | |
| RU2018134981A (ru) | Конъюгаты, содержащие ингибиторы RIPK2 | |
| JP2016537384A5 (enExample) | ||
| JP2017531039A5 (enExample) | ||
| RU2016140338A (ru) | Азаспиро производные в качестве антагонистов trpm8 | |
| CN112472699A (zh) | 改善比生群及衍生物的治疗益处的组合方法 | |
| JP2013537210A5 (enExample) | ||
| JP2002508326A5 (enExample) | ||
| HRP20121069T1 (hr) | Supstituirani derivati amida kao inhibitori protein kinaze | |
| KR20150118102A (ko) | Pi3 키나제 모듈레이터로서의 헤테로방향족 화합물 | |
| JP2004500326A (ja) | αｖインテグリン受容体拮抗薬 | |
| KR20150083833A (ko) | Pi3 키나제 모듈레이터로서의 헤테로방향족 화합물 및 이의 이용 방법 | |
| CN104513259A (zh) | 取代脲衍生物及其在药物中的应用 | |
| AR084067A1 (es) | Composiciones farmaceuticas | |
| CA3259938A1 (en) | USP1 INHIBITORS AND RELATED USES | |
| CA2557752A1 (en) | Hydroxy-6-heteroaryl-phenanthridines and their use as pde4 inhibitors |